Brain and Cognition Discovery Foundation

Recent papers from Brain and Cognition Discovery Foundation

1. Transdiagnostic patterns of electroencephalography ( EEG )‐derived aperiodic activity across schizophrenia‐spectrum, bipolar, and depressive disorders: A systematic reviewPsychiatry and Clinical Neurosciences · 2026
2. Ketamine’s Mechanisms of Action in Major Depressive Disorder and Treatment-Resistant Depression: Is Brain Topological Change a Candidate Convergent Systems-Level Pathway?Asian Journal of Psychiatry · 2026
3. Chronopharmacology and implications for the safety and efficacy of anticonvulsants, antipsychotics, and antidepressants: A systematic reviewJournal of Psychopharmacology · 2026
4. Neural and behavioral signatures of food reward processing in co-occurring depression and body fat-defined obesity: Evidence from behavioral and fMRI tasksPersonality and Individual Differences · 2026
5. The effect of ketamine on mitochondrial bioenergetics, viability, and function: A systematic reviewJournal of Psychopharmacology · 2026
6. Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental IllnessJAMA Psychiatry · 2026
7. Association Between Dextromethorphan/Bupropion with Diabetes Mellitus and Hyperglycemia: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)CNS Spectrums · 2026
8. An evaluation of aripiprazole long-acting injectable monthly and bimonthly in the maintenance treatment of bipolar I disorderTherapeutic Delivery · 2026
9. Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic reviewJournal of Psychopharmacology · 2026
10. Investigating the effects of antidepressants on measures of insulin resistance in major depressive disorder: A systematic reviewJournal of Affective Disorders · 2026
11. Ketamine for the Treatment of Obsessive-Compulsive Disorder (OCD): A Systematic Review on Efficacy and TolerabilityClinical Neuropharmacology · 2026
12. The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of DepressionClinical Pharmacology & Therapeutics · 2026
13. Adjunctive Antipsychotics in Major Depressive DisorderJAMA Psychiatry · 2026
14. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.2026
15. Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational studyTherapeutic Advances in Psychopharmacology · 2026
16. Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic reviewGeneral Hospital Psychiatry · 2026
17. Psychomotor Disturbance as a Predictor of Treatment Response in Mood Disorders: A Systematic ReviewDisease and Therapeutics · 2026
18. Exploratory characterization of gut microbiota and cognitive profiles in adolescents with subthreshold depression: a shotgun metagenomics sequencing studynpj Mental Health Research · 2026
19. The effect of GLP-1 receptor agonists on anxiety: A systematic reviewPsychoneuroendocrinology · 2026
20. Association of Glucagon-Like Peptide-1 Receptor Agonists and Suicidality: A Systematic Review.2026